Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …

Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these …

Immunotherapy has revolutionized the clinical management of many malignancies but is
infrequently associated with durable objective responses when used as a standalone …

Cancer progresses by evading the immune system. Elucidating diverse immune evasion
strategies is a critical step in the search for next-generation immunotherapies for cancer …

Abstract Introduction In CheckMate 227, nivolumab plus ipilimumab prolonged overall
survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD …

To identify novel cancer therapies, the tumor microenvironment (TME) has received a lot of
attention in recent years in particular with the advent of clinical successes achieved by …

CD8+ T cells specific for cancer cells are detected within tumours. However, despite their
presence, tumours progress. The clinical success of immune checkpoint blockade and …

Biomedical polymers have been extensively developed for promising applications in a lot of
biomedical fields, such as therapeutic medicine delivery, disease detection and diagnosis …